Life Sciences Tools and Services
Company Overview of Second Genome, Inc.
Second Genome, Inc., a life sciences company, develops microbiome-modulating precision therapies. Its microbiome signature discovery services include solutions for microbiome analysis, such as biological specimen storage and sample preparation; sequencing (NGS) and array-based metagenomic assays; and bioinformatics pipelines. Second Genome, Inc. was formerly known as PhyloTech, Inc. and changed its name to Second Genome, Inc. in January 2011. The company was founded in 2009 and is based in San Bruno, California.
1150 Bayhill Drive
San Bruno, CA 94066
Founded in 2009
Key Executives for Second Genome, Inc.
Chief Executive Officer and President
Co-Founder and Chairman of the Board
Co-Founder and Chairperson of Scientific Advisory Board
Co-Founder and Head of Bioinformatics
Senior Vice President of Corporate Development
Compensation as of Fiscal Year 2014.
Second Genome, Inc. Key Developments
Second Genome, Inc. Presents at 17th Annual BIO CEO & Investor Conference, Feb-10-2015 08:00 AM
Jan 20 15
Second Genome, Inc. Presents at 17th Annual BIO CEO & Investor Conference, Feb-10-2015 08:00 AM. Venue: The Waldorf Astoria, New York, New York, United States. Speakers: Karim Dabbagh, Chief Scientific Officer.
Second Genome, Inc. Presents at Life Sciences Summit 2014, Oct-29-2014 10:00 AM
Oct 22 14
Second Genome, Inc. Presents at Life Sciences Summit 2014, Oct-29-2014 10:00 AM. Venue: 10 on the Park at Time Warner Center, 60 Columbus Circle, 10th Floor, New York, NY 10019, United States. Speakers: Peter B. DiLaura, Chief Executive Officer and President.
Second Genome, Inc. and Mayo Clinic Enter Collaboration to Develop Microbiome Therapeutics in Multiple Diseases
Oct 7 14
Second Genome, Inc. announced that it has entered into an extensive partnership with the Mayo Clinic Center for Individualized Medicine to support the development of therapeutic products for multiple disease indications, starting with inflammatory bowel disease, metabolic disorders, and colorectal cancer. Under the terms of the agreement, the company will identify up to eight clinical indications where the microbiome has a potential role in disease and will collaborate on microbiome research with Mayo Clinic investigators who specialize in each of the designated disease areas. Mayo Clinic will provide human clinical samples from patients in targeted disease areas, and the company will deploy its proprietary microbiome discovery platform to identify biological pathways implicated in disease. Further, the company will utilize its platform to discover novel therapies that target these microbiome-mediated pathways. Mayo Clinic will make an equity investment in the company as part of the collaboration. Financial details were not disclosed. This collaboration enables the company to access Mayo Clinic's clinical and research expertise in retrospective and prospective studies across a range of diseases. It specifically strengthens the company’s current drug discovery programs in inflammatory bowel disease and metabolic disease, while supporting the company's move into new areas such as colorectal cancer.
Similar Private Companies By Industry
Recent Private Companies Transactions
October 7, 2014